ArticlePLoS neglected tropical diseases2015
Acceptability and Willingness-to-Pay for a Hypothetical Ebola Virus Vaccine in Nigeria.
Article in PLoS neglected tropical diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Acceptability of the Ebola vaccine in the sub-Saharan African population: A systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- Awareness, acceptability, and willingness to pay for the R21/Matrix-M malaria vaccine: a cross-sectional study among pregnant women and nursing mothers in Enugu State, Nigeria.BMC public health · 2025Article
- Factors influencing COVID-19 vaccine acceptability among household heads in northern Nigeria: a community-based cross-sectional study.BMJ open · 2025Article
- Exploring perceptions and attitudes towards vaccines in a remote western DRC health zone.Vaccine: X · 2025Article
- Article
- Public perceptions of Ebola vaccines and confidence in health services to treat Ebola, malaria, and tuberculosis: Findings from a cross-sectional household survey in Uganda, 2020.PLOS global public health · 2023Article
- Factors That Impact Acceptance of COVID-19 Vaccination in Different Community-Dwelling Populations in China.Vaccines · 2022Article
- Article
- Article
- COVID-19 vaccine hesitancy and willingness to pay: Emergent factors from a cross-sectional study in Nigeria.Vaccine: X · 2021Article
- Immediate and informative feedback during a pandemic: Using stated preference analysis to predict vaccine uptake rates.Health economics · 2021Article
- The demand for a COVID-19 vaccine in Kenya.Human vaccines & immunotherapeutics · 2021Article
- 'Learn from the lessons and don't forget them': identifying transferable lessons for COVID-19 from meningitis A, yellow fever and Ebola virus disease vaccination campaigns.BMJ global health · 2021Review
- Article
- Article
- When it is available, will we take it? Social media users' perception of hypothetical COVID-19 vaccine in Nigeria.The Pan African medical journal · 2021Article
- The demand for a COVID-19 vaccine in Ecuador.Vaccine · 2020Article
- Willingness-to-pay for a COVID-19 vaccine and its associated determinants in Indonesia.Human vaccines & immunotherapeutics · 2020Article
- Article
- Mothers' willingness to accept and pay for vaccines to their children in western Iran: a contingent valuation study.BMC pediatrics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEbola virus disease is a highly virulent and transmissible disease. The largest recorded fatality from Ebola virus disease epidemic is ongoing in a few countries in West Africa, and this poses a health risk to the entire population of the world because arresting the transmission has been challenging. Vaccination is considered a key intervention that is capable of arresting further spread of the disease and preventing future outbreak. However, no vaccine has yet been approved for public use, although various recombinant vaccines are undergoing trials and approval for public use is imminent. Therefore, this study aimed to determine the acceptability of and willingness-to-pay for Ebola virus vaccine by the public.
methodsThe study was a community-based cross-sectional qualitative and quantitative interventional study conducted in two communities, each in two states in Nigeria. An interviewer-administered questionnaire was used to collect information on respondents' knowledge of the Ebola virus, the ways to prevent the disease, and their preventive practices, as well as their acceptability of and willingness-to-pay for a hypothetical vaccine against Ebola virus disease. The association between acceptability of the vaccine and other independent variables were evaluated using multivariate regression analysis.
resultsEbola virus disease was considered to be a very serious disease by 38.5% of the 582 respondents (224/582), prior to receiving health education on Ebola virus and its vaccine. Eighty percent (80%) accepted to be vaccinated with Ebola vaccine. However, among those that accepted to be vaccinated, most would only accept after observing the outcome on others who have received the vaccine. More than 87.5% was willing to pay for the vaccine, although 55.2% was of the opinion that the vaccine should be provided free of charge.
conclusionThe level of acceptability of Ebola virus vaccine among respondents was impressive (though conditional), as well as their willingness to pay for it if the vaccine is not publicly funded. In order to achieve a high uptake of the vaccine, information and education on the vaccine should be extensively shared with the public prior to the introduction of the vaccine, and the vaccine should be provided free of charge by government.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.